PAPER Tseng WI, Hsu YC, Huang LK, Hong CT, Lu YH, Chen JH, Fu CK, Chan L
SEARCH RESULTS
330883 RESULTS
PAPER Gabb VG, Blackman J, Morrison HD, Biswas B, Li H, Turner N, Russell GM, Greenwood R, Jolly A, Trender W, Hampshire A, Whone A, Coulthard E
Remote Evaluation of Sleep and Circadian Rhythms in Older Adults With Mild Cognitive Impairment and Dementia: Protocol for a Feasibility and Acceptability Mixed Methods Study.
JMIR Res Protoc. 2024 Mar 22;13:e52652. PubMed: 38517469PAPER Salvadó G, Horie K, Barthélemy NR, Vogel JW, Pichet Binette A, Chen CD, Aschenbrenner AJ, Gordon BA, Benzinger TL, Holtzman DM, Morris JC, Palmqvist S, Stomrud E, Janelidze S, Ossenkoppele R, Schindler SE, Bateman RJ, Hansson O
Disease staging of Alzheimer's disease using a CSF-based biomarker model.
Nat Aging. 2024 Mar 21; PubMed: 38514824PAPER Fujita M, Gao Z, Zeng L, McCabe C, White CC, Ng B, Green GS, Rozenblatt-Rosen O, Phillips D, Amir-Zilberstein L, Lee H, Pearse RV 2nd, Khan A, Vardarajan BN, Kiryluk K, Ye CJ, Klein HU, Wang G, Regev A, Habib N, Schneider JA, Wang Y, Young-Pearse T, Mostafavi S, Bennett DA, Menon V, De Jager PL
Cell subtype-specific effects of genetic variation in the Alzheimer's disease brain.
Nat Genet. 2024 Apr;56(4):605-614. Epub 2024 Mar 21 PubMed: 38514782PAPER Ortiz de Ora L, Balsamo JM, Uyeda KS, Bess EN
Discovery of a Gut Bacterial Metabolic Pathway that Drives α-Synuclein Aggregation.
ACS Chem Biol. 2024 Apr 19;19(4):1011-1021. Epub 2024 Mar 22 PubMed: 38517270PAPER Ruan Y, Zheng D, Guo W, Cao X, Qi W, Yuan Q, Zhang X, Liang X, Zhang D, Xue C, Xiao C, and the Alzheimer’s Disease Neuroimaging Initiative
Shared and Specific Changes of Cortico-Striatal Functional Connectivity in Stable Mild Cognitive Impairment and Progressive Mild Cognitive Impairment.
J Alzheimers Dis. 2024;98(4):1301-1317. PubMed: 38517789PAPER Zhang M, Qu Y, Li Q, Gu C, Zhang L, Chen H, Ding M, Zhang T, Zhen R, An H
Correlation Between Prefrontal Functional Connectivity and the Degree of Cognitive Impairment in Alzheimer's Disease: A Functional Near-Infrared Spectroscopy Study.
J Alzheimers Dis. 2024;98(4):1287-1300. PubMed: 38517784PAPER Li Y, Xu X, Wang P, Chen X, Yang Q, Sun L, Gao X
Association of Cancer History with Lifetime Risk of Dementia and Alzheimer's Disease.
J Alzheimers Dis. 2024;98(4):1319-1328. PubMed: 38517790PAPER Chen JH, Yin X, He H, Lu LW, Wang M, Liu B, Cheng KW
Potential neuroprotective benefits of plant-based fermented foods in Alzheimer's disease: an update on preclinical evidence.
Food Funct. 2024 Apr 22;15(8):3920-3938. PubMed: 38517682NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) (RFA-RM-24-002)
GRANT Friday, March 22, 2024- 8:30pm National Institutes of Health NIH intends to commit approximately $8,000,000 in FY 2025 to fund approximately 7 awards. Awards will be for $700,000 in Direct Costs per year, plus applicable Facilities and Administrative cost
NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) (RFA-RM-24-003)
GRANT Friday, March 22, 2024- 8:30pm National Institutes of Health NIH intends to commit approximately $37.7 million for approximately 30 awards in FY 2025. Awards will be in two multi-year segments, the first of three years followed by a segment of two years.
NIH Directors Transformative Research Awards (R01 Clinical Trial Optional) (RFA-RM-24-004)
GRANT Friday, March 22, 2024- 8:30pm National Institutes of Health NIH intends to commit approximately $8 million in FY 2025 and make approximately 7 awards, depending on the size and scope of the most meritorious awards. Application budgets are not limited but
NIH Directors Early Independence Awards (DP5 Clinical Trial Optional) (RFA-RM-24-005)
GRANT Friday, March 22, 2024- 8:30pm National Institutes of Health Awards will be for up to $250,000 in Direct Costs per year, plus applicable Facilities and Administrative (F&A) costs. The project period is limited to five years. September 06, 2024 https:/
Lon S. Schneider on TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative, Again
COMMENT This may have been the fourth randomized Phase 3 trial of a form of methylene blue in various doses by this company. None was statistically significant compared to their contemporaneous controls. The trials used a small dose of HMTM or similar as the cont
TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative, Again
CONFERENCE COVERAGE 2024-03-22 Conference Coverage Old drugs die hard. Despite a string of negative Phase 3 trials, HMTM, a derivative of the malaria drug methylene blue, resurfaced again at AD/PD 2024, held March 5-9 in Lisbon, Portugal. TauRx CEO Claude Wischik reported results from
Current Filters
- Date Range : All x